CA1251708A - Systeme de dispension constante a modulation pulsee - Google Patents

Systeme de dispension constante a modulation pulsee

Info

Publication number: CA1251708A
Authority: CA; Canada
Prior art keywords: delivery; agent; osmotic; beneficial agent; pulsed
Prior art date: 1983-12-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000468135A

Other languages

English (en)

Inventor

Paul R. Magruder

Patrick S.L. Wong

Felix Theeuwes

Brian Barclay

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Alza Corp

Original Assignee

Alza Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-12-01

Filing date

1984-11-19

Publication date

1989-03-28

1984-11-19 Application filed by Alza Corp filed Critical Alza Corp

1989-03-28 Application granted granted Critical

1989-03-28 Publication of CA1251708A publication Critical patent/CA1251708A/fr

Status Expired legal-status Critical Current

Links

230000003204 osmotic effect Effects 0.000 claims abstract description 115
239000003795 chemical substances by application Substances 0.000 claims description 169
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 47
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 36
239000003814 drug Substances 0.000 claims description 36
229960002052 salbutamol Drugs 0.000 claims description 36
229940079593 drug Drugs 0.000 claims description 35
230000009286 beneficial effect Effects 0.000 claims description 31
239000000203 mixture Substances 0.000 claims description 23
239000011780 sodium chloride Substances 0.000 claims description 23
239000012530 fluid Substances 0.000 claims description 17
231100000252 nontoxic Toxicity 0.000 claims description 6
230000003000 nontoxic effect Effects 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
239000000463 material Substances 0.000 claims description 4
150000007524 organic acids Chemical class 0.000 claims description 3
150000007522 mineralic acids Chemical class 0.000 claims description 2
235000002639 sodium chloride Nutrition 0.000 description 27
238000000034 method Methods 0.000 description 19
239000004615 ingredient Substances 0.000 description 18
-1 hydroxypropyl Chemical group 0.000 description 16
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 12
229920002301 cellulose acetate Polymers 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
239000000975 dye Substances 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
239000000047 product Substances 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
229920002678 cellulose Polymers 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
229960002122 acebutolol Drugs 0.000 description 6
GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 6
239000001913 cellulose Substances 0.000 description 6
238000012377 drug delivery Methods 0.000 description 6
239000008187 granular material Substances 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 6
239000000725 suspension Substances 0.000 description 6
229920002785 Croscarmellose sodium Polymers 0.000 description 5
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 5
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 5
239000013583 drug formulation Substances 0.000 description 5
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
230000001186 cumulative effect Effects 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000000243 solution Substances 0.000 description 4
CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 3
BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
229940124630 bronchodilator Drugs 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000002537 cosmetic Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
235000013305 food Nutrition 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
229960004570 oxprenolol Drugs 0.000 description 3
230000035699 permeability Effects 0.000 description 3
239000011148 porous material Substances 0.000 description 3
239000001103 potassium chloride Substances 0.000 description 3
235000011164 potassium chloride Nutrition 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000004659 sterilization and disinfection Methods 0.000 description 3
230000036962 time dependent Effects 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
239000013543 active substance Substances 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000013329 compounding Methods 0.000 description 2
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
238000005553 drilling Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
230000035558 fertility Effects 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
235000016337 monopotassium tartrate Nutrition 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000002357 osmotic agent Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
230000009467 reduction Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000012047 saturated solution Substances 0.000 description 2
230000028327 secretion Effects 0.000 description 2
VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
229960005105 terbutaline sulfate Drugs 0.000 description 2
KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
NTJPVVKEZMOHNU-UHFFFAOYSA-N 6-(oxan-4-yl)-1h-indazole Chemical compound C1COCCC1C1=CC=C(C=NN2)C2=C1 NTJPVVKEZMOHNU-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920008347 Cellulose acetate propionate Polymers 0.000 description 1
229920001747 Cellulose diacetate Polymers 0.000 description 1
229920002284 Cellulose triacetate Polymers 0.000 description 1
102000009660 Cholinergic Receptors Human genes 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
241000207199 Citrus Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
241001494479 Pecora Species 0.000 description 1
RXBKMJIPNDOHFR-UHFFFAOYSA-N Phenelzine sulfate Chemical compound OS(O)(=O)=O.NNCCC1=CC=CC=C1 RXBKMJIPNDOHFR-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000288906 Primates Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960003830 acebutolol hydrochloride Drugs 0.000 description 1
KTUFKADDDORSSI-UHFFFAOYSA-N acebutolol hydrochloride Chemical compound Cl.CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 KTUFKADDDORSSI-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000674 adrenergic antagonist Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000003619 algicide Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000078 anti-malarial effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000003139 biocide Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
125000006309 butyl amino group Chemical group 0.000 description 1
238000003490 calendering Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000002371 cardiac agent Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
229920006217 cellulose acetate butyrate Polymers 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
230000002070 germicidal effect Effects 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
230000002363 herbicidal effect Effects 0.000 description 1
239000004009 herbicide Substances 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229940125697 hormonal agent Drugs 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
239000005554 hypnotics and sedatives Substances 0.000 description 1
229940005535 hypnotics and sedatives Drugs 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
239000002917 insecticide Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000011147 magnesium chloride Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
HNEGQIOMVPPMNR-NSCUHMNNSA-N mesaconic acid Chemical compound OC(=O)C(/C)=C/C(O)=O HNEGQIOMVPPMNR-NSCUHMNNSA-N 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
HNEGQIOMVPPMNR-UHFFFAOYSA-N methylfumaric acid Natural products OC(=O)C(C)=CC(O)=O HNEGQIOMVPPMNR-UHFFFAOYSA-N 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
235000019321 monosodium tartrate Nutrition 0.000 description 1
238000000465 moulding Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
229960004790 phenelzine sulfate Drugs 0.000 description 1
230000008635 plant growth Effects 0.000 description 1
239000002373 plant growth inhibitor Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229940081543 potassium bitartrate Drugs 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
229910052939 potassium sulfate Inorganic materials 0.000 description 1
235000011151 potassium sulphates Nutrition 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000003236 psychic effect Effects 0.000 description 1
238000004080 punching Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
239000002356 single layer Substances 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229940119126 sodium bitartrate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
235000010344 sodium nitrate Nutrition 0.000 description 1
239000004317 sodium nitrate Substances 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
JMHRGKDWGWORNU-UHFFFAOYSA-M sodium;2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound [Na+].CC1=C(CC([O-])=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 JMHRGKDWGWORNU-UHFFFAOYSA-M 0.000 description 1
239000011973 solid acid Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
FTNWXGFYRHWUKG-UHFFFAOYSA-N triflupromazine hydrochloride Chemical compound [H+].[Cl-].C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 FTNWXGFYRHWUKG-UHFFFAOYSA-N 0.000 description 1
229960004312 triflupromazine hydrochloride Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
238000005303 weighing Methods 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Preparation (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)

CA000468135A 1983-12-01 1984-11-19 Systeme de dispension constante a modulation pulsee Expired CA1251708A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55698583A	1983-12-01	1983-12-01
US06/556,985		1983-12-01

Publications (1)

Publication Number	Publication Date
CA1251708A true CA1251708A (fr)	1989-03-28

Family

ID=24223601

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000468135A Expired CA1251708A (fr)	1983-12-01	1984-11-19	Systeme de dispension constante a modulation pulsee

Country Status (7)

Country	Link
JP (2)	JP2504396B2 (fr)
CA (1)	CA1251708A (fr)
DE (1)	DE3443586C2 (fr)
ES (4)	ES538104A0 (fr)
FR (1)	FR2555897B1 (fr)
GB (1)	GB2150434B (fr)
IT (1)	IT1179843B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH075457B2 (ja) *	1983-08-16	1995-01-25	ザウエルカムフアウンデ−シヨンリミテツド	調節された方法による有効成分の放出を可能にする医薬組成物
FR2598614A1 (fr) *	1986-05-14	1987-11-20	Alza Corp	Systeme osmotique pour l'apport menage d'haloperidol
US4627851A (en) *	1984-10-26	1986-12-09	Alza Corporation	Colonic-therapeutic delivery system
US4723958A (en) *	1986-05-23	1988-02-09	Merck & Co., Inc.	Pulsatile drug delivery system
DD295760A5 (de) *	1989-01-31	1991-11-14	Martin-Luther-Universitaet Halle Wittenberg,De	Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
FI900470A7 (fi) *	1989-01-31	1990-08-01	Ipa Int Pharma Agentur Gmbh	Aktiiviaineita säädetysti vapauttava systeemi ja menetelmä sen valmistamiseksi
JP4848101B2 (ja) *	2001-08-17	2011-12-28	株式会社フジモト・コーポレーション	徐放性マイクロペレット
WO2010015840A1 (fr) *	2008-08-08	2010-02-11	Cipla Limited	Dispositif d'administration osmotique avec libération modifiée

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU466503B2 (en) *	1972-06-05	1975-10-30	Alza Corporation	Osmotic dispenser
US3952741A (en) *	1975-01-09	1976-04-27	Bend Research Inc.	Controlled release delivery system by an osmotic bursting mechanism
US4036228A (en) *	1975-09-11	1977-07-19	Alza Corporation	Osmotic dispenser with gas generating means
US4265874A (en) *	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
US4326525A (en) *	1980-10-14	1982-04-27	Alza Corporation	Osmotic device that improves delivery properties of agent in situ

1984
- 1984-10-24 GB GB08426842A patent/GB2150434B/en not_active Expired
- 1984-11-19 CA CA000468135A patent/CA1251708A/fr not_active Expired
- 1984-11-22 FR FR8417798A patent/FR2555897B1/fr not_active Expired
- 1984-11-29 ES ES538104A patent/ES538104A0/es active Granted
- 1984-11-29 DE DE3443586A patent/DE3443586C2/de not_active Expired - Lifetime
- 1984-11-30 IT IT68196/84A patent/IT1179843B/it active Protection Beyond IP Right Term
- 1984-11-30 JP JP59253946A patent/JP2504396B2/ja not_active Expired - Lifetime
1985
- 1985-08-09 ES ES546059A patent/ES8801984A1/es not_active Expired
- 1985-08-09 ES ES1985295960U patent/ES295960Y/es not_active Expired
1986
- 1986-03-17 ES ES1986293000U patent/ES293000Y/es not_active Expired
1993
- 1993-10-13 JP JP5256175A patent/JP2683493B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
GB8426842D0 (en)	1984-11-28
ES8602390A1 (es)	1985-12-01
ES293000Y (es)	1987-03-16
IT8468196A1 (it)	1986-05-30
ES546059A0 (es)	1988-03-16
FR2555897B1 (fr)	1988-05-13
IT8468196A0 (it)	1984-11-30
FR2555897A1 (fr)	1985-06-07
ES8801984A1 (es)	1988-03-16
JP2504396B2 (ja)	1996-06-05
IT1179843B (it)	1987-09-16
ES538104A0 (es)	1985-12-01
ES295960U (es)	1988-01-01
GB2150434A (en)	1985-07-03
GB2150434B (en)	1987-11-04
ES293000U (es)	1986-07-01
ES295960Y (es)	1988-07-16
JPH0733642A (ja)	1995-02-03
DE3443586C2 (de)	1996-09-05
JP2683493B2 (ja)	1997-11-26
JPS60185711A (ja)	1985-09-21
DE3443586A1 (de)	1985-06-13

Legal Events

Date	Code	Title	Description
2006-03-28	MKEX	Expiry

Publication	Publication Date	Title
US4777049A (en)	1988-10-11	Constant release system with pulsed release
US4851229A (en)	1989-07-25	Composition comprising a therapeutic agent and a modulating agent
EP1246613B1 (fr)	2010-10-13	Dispositif osmotique place a l'interieur d'un autre dispositif osmotique
US4519801A (en)	1985-05-28	Osmotic device with wall comprising cellulose ether and permeability enhancer
CA2396258C (fr)	2008-05-13	Systeme de distribution de medicament par pompage osmotique/diffusion combines
US4553973A (en)	1985-11-19	Process for preparing osmotic device
US6753011B2 (en)	2004-06-22	Combined diffusion/osmotic pumping drug delivery system
US4751071A (en)	1988-06-14	Composition comprising salbutamol
CA2101245C (fr)	2002-06-25	Formes pharmaceutiques comprenant des polymeres de differents poids moleculaires
DK175899B1 (da)	2005-05-30	Matrixindretning til styret afgivelse af mindst et aktivt middel til et omgivende miljö og fremgangsmåder til fremstilling og anvendelse deraf
US3952741A (en)	1976-04-27	Controlled release delivery system by an osmotic bursting mechanism
US4203439A (en)	1980-05-20	Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
EP0238189B1 (fr)	1991-01-02	Verapamil en capsule de diffusion
US4732915A (en)	1988-03-22	Process for increasing solubility of drug
JPS59167513A (ja)	1984-09-21	速効性浸透圧利用薬剤放出システム
US4610686A (en)	1986-09-09	Controlled delivery of haloperidol by an osmotic delivery system
AT394311B (de)	1992-03-10	Pharmazeutische dosierungsform zur kontrollierten abgabe von diltiazem
GB2150434A (en)	1985-07-03	Constant rate release systems
JP2559106B2 (ja)	1996-12-04	アスコルビン酸カルシウムの投与装置
EP0247709A1 (fr)	1987-12-02	Chlorpheniramine thérapie